Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The India contract development and manufacturing organization (CDMO) market was valued at USD 25.51 Billion in 2025 driven by large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry across the region. It is expected to grow at a CAGR of 10.80% during the forecast period of 2026-2035 and attain a market value of USD 71.14 Billion by 2035. In addition, the rising demand for complex biologics, global expansion strategies by Indian CDMOs, and increasing collaborations are driven by regulatory alignment with major markets like the U.S. and EU.
Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance. That foundation is now being applied to more advanced services, including biologics, cell and gene therapies, and niche formulations like antibody-drug conjugates (ADCs). As global demand for these therapies grows, Indian firms are investing in high-containment facilities, single-use bioreactors, and integrated R&D platforms to support the shift.
Key Market Trends and Insights
- India’s expanding biologics capabilities are attracting global pharmaceutical firms seeking cost-effective, high-quality development and manufacturing partnerships.
- The market growth is driven by the rising demand for oncology and specialty drug outsourcing, driving investment in India’s advanced therapeutic manufacturing infrastructure.
- One of the major market trends include rising government support and regulatory harmonization, enhancing India’s global appeal as a reliable and scalable CDMO destination.
Market Size and Forecast
- Market Size in 2025: USD 25.51 Billion
- Projected Market Size in 2035: USD 71.14 Billion
- Compound Annual Growth Rate (CAGR) of 2026 to 2035: 10.80%
Compound Annual Growth Rate
10.8%
Value in USD Billion
2026-2035
India Contract Development and Manufacturing Organization (CDMO) Market Overview
Contract development and manufacturing organizations (CDMOs) play a vital role in India's pharmaceutical and medical device industries by offering end-to-end services from research and development to commercial-scale manufacturing. They enable companies to reduce operational costs, accelerate product development, and comply with stringent global regulatory standards. With India's strong manufacturing capabilities, skilled workforce, and supportive policies, CDMOs attract both domestic and international clients. Their presence enhances innovation, efficiency, and global competitiveness, significantly contributing to the growth of India’s life sciences sector. The market is expected to grow at a CAGR of 10.80% during the forecast period of 2026-2035 and attain a market value of USD 71.14 Billion by 2035.
What are the Drivers for India Contract Development and Manufacturing Organization (CDMO) Market Growth?
Programs Based on Strengthening India’s Clinical Research and CDMO Capabilities to Boost Market Growth
In February 2025, Avance Clinical, an Australian CRO, established a specialized biometrics hub in Bangalore to enhance its GlobalReady program. This expansion focuses on statistical programming and data analytics to accelerate early-phase clinical trials for biotech companies in the United States and Australia. As demand for outsourced clinical research rises and India remains a hub for skilled talent and cost-effective services, this move is expected to elevate India’s global standing in the CRO and CDMO markets during the forecast period.
Biologics Manufacturing Advancements to Meet Rising India Contract Development and Manufacturing Organization (CDMO) Market Demand
In January 2025, Shilpa Biologicals inaugurated a new bioconjugation manufacturing facility in Karnataka (a Southern state in India), joining the global league of CDMOs offering integrated antibody-drug conjugate (ADC) capabilities. This complements its existing cytotoxic fill-finish site in Hyderabad and positions India as a growing hub for complex biologics manufacturing. With increasing demand for high-quality, cost-efficient biologics production, such infrastructure upgrades are expected to attract international partnerships and boost the growth and global competitiveness of India’s CDMO market.
What are the India Contract Development and Manufacturing Organization (CDMO) Market Trends?
Piramal Pharma Solutions launched a new Band 5 containment spray drying suite at its dedicated peptide development and manufacturing facility in Turbhe, Maharashtra, in August 2026. The new suite is equipped with dedicated air-handling units, nitrogen supply and control systems, enabling the company to support challenging formulations involving peptides, highly potent APIs and other biomolecules. The expansion strengthens Piramal’s ability to provide development and manufacturing services for complex molecules and adds specialised formulation infrastructure alongside its existing peptide API capabilities.
Gland Pharma and Neuland Laboratories entered into a long-term strategic CDMO partnership in August 2026 to expand manufacturing of sterile APIs for complex injectable therapies. Under the arrangement, Gland Pharma will establish a dedicated sterile manufacturing suite at its Jawaharlal Nehru Pharma City facility in Visakhapatnam. The new suite is expected to add approximately 1,400 kg of annual capacity and will be designed to meet cGMP, US FDA and European Union requirements. The partnership combines Neuland’s expertise in complex API development and scale-up with Gland Pharma’s sterile manufacturing capabilities.
Hikal inaugurated a new cGMP-compliant pilot plant at its Research and Technology campus in Pune in July 2026. The facility is designed to strengthen pharmaceutical development and contract manufacturing services for global customers, supporting process development, technology transfer and clinical-stage manufacturing. The new infrastructure enables Hikal to move projects from laboratory development toward larger-scale production under regulated manufacturing conditions. The investment also expands the company’s ability to support pharmaceutical innovators requiring flexible development and manufacturing capacity before commercial-scale production.
Aurobindo Pharma inaugurated the first manufacturing facility of its biologics CDMO arm, TheraNym, at Borapatla in Telangana in June 2026. The facility is equipped with 15,000-litre bioreactors, downstream processing suites, aseptic fill-finish capabilities and quality-control laboratories. Aurobindo has also onboarded Merck as its first partner, with the facility expected to supply three commercial-stage products for domestic and export markets. The development expands Aurobindo’s CDMO presence into biologics manufacturing and provides infrastructure covering upstream processing, downstream purification and sterile drug-product manufacturing.
Shift Toward Complex Biologics and Biosimilars
Indian CDMOs are increasingly expanding beyond conventional small-molecule APIs into biologics, biosimilars and other complex pharmaceutical modalities. The Biopharma SHAKTI scheme, announced in 2026 with an outlay of INR 10,000 crore over five years, specifically targets domestic biologics and biosimilar manufacturing, alongside biopharma R&D and clinical-trial infrastructure. The initiative includes an emerging biologics manufacturing programme and support for fermentation-based manufacturing. This policy direction is encouraging Indian CDMOs to invest in specialised fermentation, cell-culture, downstream processing and aseptic manufacturing capabilities, while creating opportunities to serve multinational pharmaceutical and biotechnology companies seeking cost-efficient outsourced production.
Rising Investment in Complex Molecule Platforms
Indian CDMOs are increasingly investing in specialised platforms for peptides, highly potent APIs, antibody-drug conjugates and other complex molecules. The trend reflects growing demand for outsourcing partners capable of managing technically demanding products from process development through commercial manufacturing. Industry discussions in 2026 identified complex modalities as a strategic area for India’s CRDMO expansion, while companies are adding capabilities across development, scale-up and manufacturing. This is encouraging a shift from capacity-based outsourcing toward expertise-led services, where CDMOs differentiate themselves through containment infrastructure, specialised analytical capabilities, process chemistry and integrated development-to-manufacturing services.
Greater Adoption of AI and Digital Manufacturing
Artificial intelligence and digital technologies are becoming increasingly important within India’s CDMO and CRDMO operations. Industry discussions in 2026 highlighted AI and digital twins as technologies capable of improving productivity and accelerating pharmaceutical development and manufacturing. Indian CDMOs are exploring these tools for process development, experimental optimisation, predictive maintenance, manufacturing monitoring and faster decision-making. AI is also gaining attention on the drug-discovery side, allowing service providers to support customers earlier in the development cycle. The growing emphasis on digitalisation is therefore broadening competition beyond physical manufacturing capacity toward speed, data integration and process intelligence.
Expansion of Integrated End-to-End Services
Indian CDMOs are increasingly moving toward integrated service models covering early development, process optimisation, clinical supply, commercial manufacturing and regulatory support. This approach enables pharmaceutical and biotechnology customers to reduce the number of technology transfers between specialised vendors and maintain greater continuity as molecules progress through development. India’s CRDMO sector was described by the Department of Pharmaceuticals in 2026 as having strong global outsourcing demand, with speed identified as an important differentiator. As a result, CDMOs are investing in broader capabilities and linked manufacturing infrastructure rather than relying solely on individual API or formulation contracts.
Stronger Focus on Supply Chain Resilience
Supply chain diversification is becoming an important factor in CDMO sourcing as pharmaceutical companies seek alternatives to concentrated manufacturing networks. Indian CDMOs are benefiting from this shift by expanding domestic capacity, strengthening critical API and intermediate production and adding manufacturing infrastructure for higher-value medicines. Government-supported pharmaceutical manufacturing programmes are also targeting reduced import dependence and greater domestic production of critical pharmaceutical inputs. As of June 2026, the government’s bulk-drug PLI programme had supported 48 approved projects, with 39 projects already commissioned. For CDMOs, this is encouraging deeper integration of raw-material sourcing, API production and finished-dose manufacturing within India.
What is the India Contract Development and Manufacturing Organization (CDMO) Market Segmentation?
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
- CRO
- Clinical Services
- Preclinical
- Phase I
- Phase II
- Phase III
- Phase IV
- Laboratory Services
- Analytical Services
- Bioanalytical Services
- Chemistry, manufacturing and Controls (CMC)
- Others
- Clinical Services
- CMO
- Finished Dosage Formulation (FDF) Development and Manufacturing
- Solid Dose Formulation
- Liquid Dose Formulation
- Injectable Dose Formulation
- Active Pharmaceutical Ingredient (API) Manufacturing
- High Potency (HPAPI)
- Large Molecule
- Small Molecule
- Finished Dosage Formulation (FDF) Development and Manufacturing
Market Breakup by Application
- Oncological Disease
- Cardiovascular Disease
- Infectious Disease
- Others
Market Breakup by Region
- North India
- East and Central India
- West India
- South India
India Contract Development and Manufacturing Organization (CDMO) Market Share
Oncological Diseases to Lead the Market Share by Application
Oncological diseases are projected to hold the largest market share in India's contract development and manufacturing organization (CDMO) sector due to the escalating cancer burden and the growing demand for advanced therapeutics. In 2022, India reported approximately 1.46 million new cancer cases, with projections indicating an increase to 1.57 million by 2025, reflecting a 12.8% rise over five years. This surge underscores the urgent need for innovative cancer treatments. India’s robust capabilities in developing and manufacturing complex generics, biosimilars, and antibody-drug conjugates attract global pharmaceutical companies seeking cost-effective oncology drug development. As per the analysis by Expert Market Research, the India biosimilar market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034. In contrast, while cardiovascular and infectious diseases also contribute significantly, the complexity, investment, and innovation in oncology drug pipelines continue to drive the segment’s dominance through the forecast period.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Who are the Leading Players in the India Contract Development and Manufacturing Organization (CDMO) Market?
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Syngene International Limited
Established in 1993 and headquartered in Bangalore, India, Syngene International Limited is a leading contract research, development, and manufacturing organization (CRDMO). It offers integrated services across the drug development value chain, including discovery chemistry, biology, safety assessment, and commercial manufacturing. Syngene caters to global pharmaceutical, biotechnology, and agrochemical companies. Its state-of-the-art facilities and collaborations with major multinationals such as Bristol Myers Squibb reinforce its position as a key player in India’s CDMO ecosystem.
Piramal Pharma Ltd.
Piramal Pharma Ltd., headquartered in Mumbai and established in 1988, is a global pharmaceutical company offering end-to-end contract development and manufacturing services. Through its CDMO division, Piramal Pharma Solutions, it supports drug substance and drug product development for small and large molecules. The company’s portfolio spans clinical trial supply, API manufacturing, and sterile fill-finish. With facilities across North America, Europe, and India, Piramal is recognized for its regulatory compliance and scalable manufacturing capabilities.
Divi’s Laboratories Ltd.
Founded in 1990 and headquartered in Hyderabad, Divi’s Laboratories Ltd. is one of India’s largest pharmaceutical manufacturing firms, focused on APIs, intermediates, and custom synthesis. With strong capabilities in complex chemistry and large-scale production, Divi’s serves leading global pharma companies as a trusted CDMO partner. The company operates world-class manufacturing facilities and maintains high compliance with international regulatory standards, making it a major contributor to India’s prominence in outsourced pharmaceutical development.
Laurus Synthesis Private Limited
Laurus Synthesis Private Limited, a subsidiary of Laurus Labs headquartered in Hyderabad and established in 2022, offers specialized contract research and manufacturing services. It focuses on custom synthesis, process development, and manufacturing of niche APIs and intermediates. With capabilities in high-potency APIs and complex chemistry, Laurus Synthesis supports early to late-stage development for pharmaceutical companies. The company’s scientific expertise, regulatory focus, and modern infrastructure position it as a rising player in India’s CDMO landscape.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Jubilant Pharmova Limited Company, Thermo Fisher Scientific Inc. (Patheon Pharma Services), Lonza Group AG, WuXi STA, AGC Biologics, Pfizer, Inc., and PCI Pharma Services.
Key Questions Answered in the India Contract Development and Manufacturing Organization (CDMO) Market
- What was the India contract development and manufacturing organization (CDMO) market value in 2025?
- What is the India contract development and manufacturing organization (CDMO) market forecast outlook for 2026-2035?
- What are the major factors aiding the India contract development and manufacturing organization (CDMO) market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India contract development and manufacturing organization (CDMO) market trends?
- Which service type will lead the market segment?
- Which application will lead the market segment?
- Who are the key players involved in the India contract development and manufacturing organization (CDMO) market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
